Pfizer (NYSE:PFE) said it is planning on filing a supplemental Biologics License Applications (sBLA) for its 20-valent pneumococcal conjugate vaccine candidate in infants by the end of the year.
After announcing positive data from a pivotal U.S. Phase 3 study (NCT04382326), the company said the 20vPnC vaccine candidate, if approved, would offer the broadest serotype coverage of any pneumococcal vaccine in infants.
PFE shares ticked up 3.69% to $50.08 in afternoon trading.
The 20vPnC vaccine candidate would protect against pneumococcal disease (IPD) resulting from 20 Streptococcus pneumoniae (pneumococcus) serotypes.
FDA approved the 20-valent conjugate vaccine for adults 18 and older last year. The vaccine for that demographic is known as Prevnar 20.
Earlier this year, FDA approved Merck’s (NYSE:MRK) Vaxneuvance pneumococcal 15-valent conjugate vaccine for infants and children.
In Pfizer’s Phase 3 study, the 20vPnC yielded stro…